Infertility Clinical Trial
Official title:
Comparison of Two Different Sedation Protocol During Transvaginal Oocyte Retrieval: Effects on Propofol Consumption
The effects of two different sedation protocols during transvaginal oocyte retrieval will be investigated on propofol consumption as a rescue sedative and on IVF success. One group will receive dexmedetomidine and fentanyl while the other will receive midazolam and remifentanil.
Women will be consecutively allocated into one of the following two groups using a 1:1 ratio
in order to avoid any potential source of bias.
Group DEX: women will receive dexmedetomidine (solution 4 γ/ml) continuously infused at a
dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the
start of transvaginal oocyte retrieval and will stop at the end of procedure. At that time
point, both total volume (ml) and dose (γ) of dexmedetomidine administered will be recorded.
Group MZM: women will receive remifentanil (solution 50γ/ml) continuously infused at a dose
of 0.2 γ/kg/min και midazolam 1 mg iv. Remifentanil infusion will start 10 min before the
start of transvaginal oocyte retrieval and will stop at the end of the procedure. At that
time point, both total volume (ml) and dose (γ) of remifentanil administered will be
recorded.
In both groups, in case of non-co-operation of the woman (e.g. kinetic response), propofol
will be given as a bolus rescue dose as follows: the 1st rescue dose will be 1mg/kg while all
the next doses will be 0.5 mg/kg. At the end of the procedure, the number of rescue doses and
the total rescue dose (mg) of propofol given will be recorded.
Intraoperative monitoring will include ECG, noninvasive blood pressure, SpO2, EtCO2 and depth
of sedation using BIS values and ΟΑSS scale. Also, adverse effects such as hypotension,
bradycardia, nausea & vomiting, rigidity, airway obstruction, and need for bag-mask
ventilation will be recorded. The use of vasoactive drugs will also be reported.
At the end of the procedure, the time and quality of recovery will be assessed using ΟΑSS
scale (max score=5), while postoperatively the Post Anesthesia Discharge Scoring System, as
well as woman's and gynecologist's (physician) overall satisfaction related to the sedation
techniques used, will be recorded.
Regarding the IVF outcome, the following parameters will be recorded: number of oocytes
retrieved, the percentage of mature oocytes, embryo quality, percentage of positive pregnancy
test, percentage of clinical pregnancy, the percentage of live birth.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A |